European Pharmaceutical Review

MARCH 4, 2024

Therefore, biologics identification and characterisation poses unparalleled challenges, as does their manufacturing processes and routes of administration while maintaining patient safety and clinical efficacy. Introducing virus-like particles (VLPs) is an alternative strategy for enhancing the efficacy of gene therapy applications.

FDA 94

FDA Vaccines Immunization Compounding 94

Pharma Marketing Network

APRIL 30, 2021

Protocols, which have remained substantively unchanged for over 30 years, often impose an immense burden on patient participants, largely due to the frequency of site visits. Across the board, from rheumatology to neurology, outcomes that matter most to patients, have traditionally not been captured in clinical trials.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Documentation FDA 52

ISPE

SEPTEMBER 8, 2023

It is incumbent for industry to modernize manufacturing processes to improve efficiency and increase confidence in quality assurance for the benefit of patients while introducing novel technology and modalities as the science advances.

FDA 52

FDA Dosage Documentation Communication 52